[go: up one dir, main page]

WO2007109783A3 - Inhibiteurs de pyrimidine kinase substituee - Google Patents

Inhibiteurs de pyrimidine kinase substituee Download PDF

Info

Publication number
WO2007109783A3
WO2007109783A3 PCT/US2007/064771 US2007064771W WO2007109783A3 WO 2007109783 A3 WO2007109783 A3 WO 2007109783A3 US 2007064771 W US2007064771 W US 2007064771W WO 2007109783 A3 WO2007109783 A3 WO 2007109783A3
Authority
WO
WIPO (PCT)
Prior art keywords
substituted pyrimidine
kinase inhibitors
pyrimidine kinase
substituted
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/064771
Other languages
English (en)
Other versions
WO2007109783A2 (fr
Inventor
Peter J Connolly
Shenlin Huang
Guozhang Xu
Jeannene Butler
Angel R Fuentes-Pesquera
Lee M Greenberger
Montagne Kenneth R La Jr
Ronghua Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of WO2007109783A2 publication Critical patent/WO2007109783A2/fr
Publication of WO2007109783A3 publication Critical patent/WO2007109783A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés de pyrimidine substituée de formule (I) : et leurs formes, leur synthèse et leur utilisation dans le traitement d'une maladie, d'une affection ou d'une pathologie chronique ou aiguë induite par une protéine-kinase.
PCT/US2007/064771 2006-03-23 2007-03-23 Inhibiteurs de pyrimidine kinase substituee Ceased WO2007109783A2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US78512706P 2006-03-23 2006-03-23
US60/785,127 2006-03-23
US78762706P 2006-03-30 2006-03-30
US60/787,627 2006-03-30
US83170206P 2006-07-18 2006-07-18
US60/831,702 2006-07-18

Publications (2)

Publication Number Publication Date
WO2007109783A2 WO2007109783A2 (fr) 2007-09-27
WO2007109783A3 true WO2007109783A3 (fr) 2008-08-21

Family

ID=38523325

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/064771 Ceased WO2007109783A2 (fr) 2006-03-23 2007-03-23 Inhibiteurs de pyrimidine kinase substituee

Country Status (2)

Country Link
US (1) US8013153B2 (fr)
WO (1) WO2007109783A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8153791B2 (en) * 2005-12-21 2012-04-10 Janssen Pharmaceutica N.V. Substituted pyrimidinyl oxime kinase inhibitors
US8278446B2 (en) * 2005-12-21 2012-10-02 Janssen Pharmaceutica N.V. Process for preparing substituted diaminopyrimidine oximes
CN100586429C (zh) * 2007-08-03 2010-02-03 中国科学院昆明植物研究所 一种抗抑郁药物
GB0909768D0 (en) * 2009-06-08 2009-07-22 Nanyang Polytechnic Novel compounds and uses thereof
EP2606035B1 (fr) 2010-07-29 2017-09-06 BIAL - Portela & CA., S.A. Procédé pour la synthèse de composés d'urée substitués
WO2013152313A1 (fr) 2012-04-05 2013-10-10 The Regents Of The University Of California Compositions et méthodes de traitement du cancer, de maladies et d'états sensibles à l'inhibition d'un facteur de croissance
SMT201800608T1 (it) 2012-04-24 2019-01-11 Vertex Pharma Inibitori di dna-pk
AU2013307688A1 (en) * 2012-08-29 2015-04-09 Merck Patent Gmbh Ddr2 inhibitors for the treatment of osteoarthritis
EP2727911B1 (fr) * 2012-10-31 2016-12-21 Medizinische Hochschule Hannover Nouveaux moyens et procédés de traitement du paludisme et autres troubles parasitaires
BR112015010109A2 (pt) * 2012-11-05 2017-07-11 Nant Holdings Ip Llc derivados de indol-5-ol substituídos e suas aplicações terapêuticas
AU2014244555B2 (en) 2013-03-12 2018-06-28 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
PE20161035A1 (es) 2013-03-15 2016-11-13 Global Blood Therapeutics Inc Compuestos y usos de estos para la modulacion de la hemoglobina
WO2014145403A1 (fr) * 2013-03-15 2014-09-18 Nantbio, Inc. Dérivés indol-5-ol substitués et leurs applications thérapeutiques
HUE041877T2 (hu) 2013-10-17 2019-06-28 Vertex Pharma (S)-N-Metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il)amino)propán-2-il)kinolin-4-karboxamid kokristályai és deuterált származékai DNS-PK inhibitorokként
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
EP3233086B1 (fr) 2014-12-18 2023-02-15 University of South Carolina Suppression de formation néo-intimale suite à une chirurgie vasculaire, à l'aide d'inhibiteurs de cdk8
WO2016137506A1 (fr) * 2015-02-27 2016-09-01 Nantbioscience, Inc. Dérivés de pyrimidine comme inhibiteurs de kinase et applications thérapeutiques associées
CN106045918B (zh) * 2016-06-28 2019-02-01 山东大学 具有Akt抑制活性的取代嘧啶类衍生物及其制备方法与应用
US11110108B2 (en) 2016-09-27 2021-09-07 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors
CN115124475B (zh) * 2022-07-11 2023-11-10 贵阳学院 一种嘧啶衍生物及其制备方法和用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050256111A1 (en) * 2004-05-14 2005-11-17 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US20050277652A1 (en) * 2004-02-27 2005-12-15 Eisai Co., Ltd. Novel pyridine derivative and pyrimidine derivative
US20060052604A1 (en) * 2002-12-16 2006-03-09 Astrazeneca Uk Limited Process for the Preparation of Pyrimidine Compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ101496A3 (en) * 1993-10-12 1996-11-13 Du Pont Merck Pharma N-alkyl-n-aryl-pyrimidinamines and derivatives thereof
JPH09301958A (ja) 1996-05-09 1997-11-25 Nippon Shoji Kk 新規ピリミジン化合物及び抗ロタウイルス剤
HRP20020599A2 (en) * 2000-01-18 2004-08-31 Pfizer Prod Inc Corticotropin releasing factor antagonists
US7026389B2 (en) * 2000-05-25 2006-04-11 Weyerhaeuser Company Labeling paint for use with metallic stencils on oriented strandboard finishing line
US6878714B2 (en) * 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
DK1397351T3 (da) * 2001-06-01 2010-01-18 Hoffmann La Roche Pyrimidin-, triazin- og pyrazinderivater som glutamatreceptorer
JP4510442B2 (ja) * 2001-06-26 2010-07-21 ブリストル−マイヤーズ スクイブ カンパニー ＴＮＦ−α発現のＮ−ヘテロ環インヒビター
US8153791B2 (en) * 2005-12-21 2012-04-10 Janssen Pharmaceutica N.V. Substituted pyrimidinyl oxime kinase inhibitors
US8278446B2 (en) * 2005-12-21 2012-10-02 Janssen Pharmaceutica N.V. Process for preparing substituted diaminopyrimidine oximes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060052604A1 (en) * 2002-12-16 2006-03-09 Astrazeneca Uk Limited Process for the Preparation of Pyrimidine Compounds
US20050277652A1 (en) * 2004-02-27 2005-12-15 Eisai Co., Ltd. Novel pyridine derivative and pyrimidine derivative
US20050256111A1 (en) * 2004-05-14 2005-11-17 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth

Also Published As

Publication number Publication date
WO2007109783A2 (fr) 2007-09-27
US20070254896A1 (en) 2007-11-01
US8013153B2 (en) 2011-09-06

Similar Documents

Publication Publication Date Title
WO2007109783A3 (fr) Inhibiteurs de pyrimidine kinase substituee
WO2007092879A3 (fr) Inhibiteurs de kinase thiatriazaacénaphthylène-6-carbonirile substitués
WO2007084815A3 (fr) Inhibiteurs de la thienopyrimidine kinase substituee
WO2007121154A3 (fr) Inhibiteurs de benzothiazole substitués
CY2021019I1 (el) Παραγωγα ν4-φαινυλ-κιναζολινο-4-αμινης και σχετικες ενωσεις ως αναστολεις υποδοχεα κινασης τυροσινης τυπου i erbb για τη θεραπεια υπερπολλαπλασιαστικων ασθενειων
IL266741A (en) Broton tyrosine kinase inhibitors
WO2007081630A3 (fr) Inhibiteurs substitues de la pyrimidinyl kinase
WO2008039359A3 (fr) Inhibiteurs de pyrimidine kinase bicyclique
WO2006123113A3 (fr) Composes chimiques
CY2015016I1 (el) Αναστολεις της κινασης τυροσινης του bruton
WO2007049041A8 (fr) Derives 4-(3-aminopyrazole)pyrimidine et leur utilisation en tant qu'inhibiteurs de tyrosine kinases dans le cadre d'un traitement anticancereux
WO2009006389A3 (fr) Composés utiles en tant qu'inhibiteurs de la kinase raf
WO2008076862A3 (fr) Composés organiques
AU2009270856A8 (en) Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors
WO2007105058A3 (fr) Pyrazoles
MY139689A (en) Imidazotriazines as protein kinase inhibitors
WO2007115620A3 (fr) Nouveaux composés de cyclobutyle en tant qu'inhibiteurs de kinase
WO2011046964A3 (fr) Inhibiteurs de tyrosine kinase de bruton
WO2008022286A3 (fr) petits inhibiteurs moléculaires de la kynurénine-3-monooxygénase
WO2007079164A3 (fr) Inhibiteurs de protéines kinases
WO2007108936A3 (fr) Azacyclylamines avec substitution n en tant qu'antagonistes de l'histamine-3
WO2007008704A3 (fr) Ligands des recepteurs de la melanocortine
WO2008059368A3 (fr) Composés de 2-amino pyridine
WO2007136668A3 (fr) N-benzoyle et n-benzylpyrrolidin-3-ylamines comme antagonistes de l'histamine-3
WO2008045371A3 (fr) Azacyclylamines avec substitution n en tant qu'antagonistes de l'histamine-3

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07759232

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07759232

Country of ref document: EP

Kind code of ref document: A2